+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and performance of the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR in patients with coronary artery disease CAD. This observational registry focuses on individuals treated with this specific stent and planned for a short dual antiplatelet therapy DAPT of up to 3 months. The study aims to collect real-world data on clinical outcomes including safety and effectiveness over a 12-month period. Participants in this single-arm registry have undergone percutaneous coronary intervention PCI using the Vivo ISAR stent and will receive standard care short DAPT treatment for no more than 3 months. The study does not affect treatment choices or standard care procedures. After the PCI, eligible patients will be invited to join the registry and followed up at 1 month, 3 months, and 12 months. During the study, researchers will collect baseline medical data and conduct telephonic follow-ups at 30 days, 3 months, and 12 months. These follow-ups will check on medication use, laboratory assessments, adverse events, and any further interventions. The main outcomes measured include ischemic and bleeding events at 12 months, along with secondary outcomes such as mortality, heart attacks, strokes, stent thrombosis, and need for additional vessel treatments. The total participation duration is one year from the PCI procedure.

Age: 18Years +All Genders
32 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.

Age: 18Years - 75YearsAll GendersPhase 2
81 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.

Age: 18Years - 85YearsAll GendersPhase 2
134 locations
C

Actively Recruiting

Researchers are studying severe diabetic macular oedema DMO, a condition where fluid builds up in the central part of the retina called the macula, leading to vision loss. The study compares two treatments for people with diabetes who have severe DMO, defined by a thickened macula of 400 microns or more. The goal is to find out if starting with anti-VEGF injections followed by subthreshold micropulse laser SML treatment when the macula thickness decreases below 400 microns is as effective and more cost-effective than continuing anti-VEGF injections alone. Participants are randomly assigned to one of two groups one receives anti-VEGF injections alone, which are given monthly at first and then every 1 to 3 months as needed the other group starts with anti-VEGF injections and switches to SML treatment every 2 to 3 months once the macula thickness is less than 400 microns. The anti-VEGF drugs used include ranibizumab, aflibercept, faricimab, and brolucizumab, and SML is a laser procedure that does not damage the macula. Treatment continues until the diabetic macular oedema clears. During the study, participants attend regular clinic visits for eye exams including optical coherence tomography OCT scans to measure macula thickness and vision tests to assess best-corrected visual acuity BCVA. Researchers also collect data on quality of life, safety, treatment use, and participant experiences. The primary outcome is vision measured at 104 weeks after randomisation. The study lasts about two years, with ongoing monitoring of treatment effects, side effects, and participant satisfaction to assess the potential for wider use of the combined treatment approach.

Age: 18Years +All GendersPhase 3
22 locations
U

Actively Recruiting

Healthy Volunteer

This research aims to collect daily urine samples from women who are trying to conceive to maintain the SPD Biobank. The study includes women with regular menstrual cycles who have either become pregnant or not, along with related information like age, menstrual days, and reproductive hormone levels. Volunteers will use a Clearblue Ovulation product to help identify their fertile days and support conception efforts. Participants will collect daily early morning urine samples throughout the study period, which lasts up to three menstrual cycles if pregnancy does not occur or up to day 60 if pregnancy is confirmed. They will also keep a daily diary recording their menstrual cycles, urine sample collection, and pregnancy test results. The urine samples will be sent to a clinical laboratory for hormone testing, then stored frozen in the SPD Biobank for future research and product evaluation. During the study, participants will provide urine samples and maintain their diaries as instructed. Researchers will measure hormone levels related to fertility and pregnancy from the collected samples. The study offers ongoing monitoring through sample collection and diary updates for up to 3 cycles or day 60 of pregnancy. This observational study is led by SPD Development Company Limited and includes women aged 18 and older who are actively trying to conceive.

Age: 18Years +FEMALE
1 location
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are studying the use of depemokimab as an additional treatment for adults aged 40 to 75 with moderate to severe Chronic Obstructive Pulmonary Disorder COPD who also have type 2 inflammation. The goal is to evaluate the effectiveness and safety of starting depemokimab early alongside the standard care these patients already receive. This study is a Phase 3 trial designed to better understand how depemokimab might help reduce COPD exacerbations in this specific group. Participants will be randomly assigned to receive either depemokimab or a matching placebo, both given in combination with their existing standard treatments for COPD. The treatment period lasts up to 156 weeks about 3 years, during which the study compares the rate of moderate to severe COPD flare-ups between the two groups. This trial uses a parallel design with quadruple masking to maintain objectivity and includes ongoing standard care throughout. Throughout the study, participants will have regular evaluations to monitor their lung function, symptoms, and quality of life using questionnaires like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms E-RS for COPD. The main outcome measured is the annual rate of moderate or severe exacerbations over the study period. Safety and response to treatment will be closely observed, with follow-up continuing until the primary completion date in April 2029 and final study completion in June 2029.

Age: 40Years - 75YearsAll GendersPhase 3
121 locations
L

Actively Recruiting

Researchers are collecting and evaluating long-term clinical and radiographic data to better understand the safety and performance of shoulder arthroplasty over time. This observational study focuses on various shoulder conditions including osteoarthritis, rotator cuff tears, rheumatoid arthritis, and fractures. The study will follow participants for a minimum of 10 years to gather extensive outcome information. Participants include those who have undergone or are indicated for shoulder arthroplasty. The study observes outcomes without administering specific treatments, tracking results through clinical assessments and imaging over time. There is no early limit on follow-up duration, allowing for a comprehensive long-term evaluation of the shoulder implants function. During the study, participants will undergo annual assessments using several scores such as the Constant score, ASES, Oxford Score, TESS, and MSTS. These measures evaluate shoulder function and condition throughout the study period. Participants are expected to comply with pre- and postoperative visit requirements, and their progress will be monitored for at least 10 years to assess the implants longevity and safety.

Age: 21Years +All Genders
40 locations
I

Actively Recruiting

This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.

Age: 18Years +All GendersPhase Not Applicable
39 locations
O

Actively Recruiting

Researchers are collecting detailed data over time on people with advanced non-small cell lung cancer NSCLC who have a specific genetic change called METex14 skipping alterations. This observational disease registry aims to understand how treatments and outcomes evolve for these patients, without changing their usual medical care. It is conducted across multiple countries to gather high-quality, standardized information on this particular lung cancer subgroup. Participants in this registry receive systemic therapy as determined by their doctors in routine clinical practice, without any treatments imposed by the study. Data collection starts when participants join the registry and continues through their treatment and follow-up, until death, loss to follow-up, entry into another clinical trial, or the end of the registry period. The registry does not involve administering any study drugs or interventions. Throughout the study, researchers collect information on participant demographics, clinical features including biomarker data, treatment patterns, and safety. They monitor outcomes such as tumor response using standardized criteria, overall survival, and adverse events. Data collection continues up to nearly five years to capture long-term results, providing valuable insights into real-world treatment effectiveness and patient safety over time.

All AgesAll Genders
80 locations

1-10 of 13

1